期刊文献+

Recent advances in nanomaterials for sonodynamic therapy 被引量:5

原文传递
导出
摘要 Sonodynamic therapy(SDT),as a novel non-invasive strategy for eliminating tumor,has the advantages of deeper tissue penetration,fewer side effects,and better patient compliance,compared with photodynamic therapy(PDT).In SDT,ultrasound was used to activate sonosensitizer to produce cytotoxic reactive oxygen species(ROS),induce the collapse of vacuoles in solution,and bring about irreversible damage to cancer cells.In recent years,much effort has been devoted to developing highly efficient sonosensitizers which can efficiently generate ROS.However,the traditional organic sonosensitizers,such as porphyrins,hypericin,and curcumins,suffer from complex synthesis,poor water solubility,and low tumor targeting efficacy which limit the benefits of SDT.In contrast,inorganic sonosensitizers show good in vivo stability,controllable physicochemical properties,ease of achieving multifunctionality,and high tumor targeting,which greatly expanded their application in SDT.In this review,we systematically summarize the nanomaterials which act as the carrier of molecular sonosensitizers,and directly produce ROS under ultrasound.Moreover,the prospects of inorganic nanomaterials for SDT application are also discussed.
出处 《Nano Research》 SCIE EI CAS CSCD 2020年第11期2898-2908,共11页 纳米研究(英文版)
基金 supported by the National Natural Science Foundation of China(No.61805287) National Science Foundation of Hunan Province,China(No.2019JJ50824) the Fundamental Research Funds for Central Universities of the Central South University(Nos.202045002,2019zzts432 and 2020CX021).
  • 相关文献

参考文献8

二级参考文献133

  • 1Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5, 219-234.
  • 2Kirkin, V.; Joos, S.; Zornig, M. The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta-Mol. Cell Res. 2004, 1644,229-249.
  • 3Kruh, G. D. Introduction to resistance to anticancer agents. Oncogene 2003, 22, 7262-7264.
  • 4Calderwood, S. K.; Khaleque, M. A.; Sawyer, D. B.; Ciocca, D. R. Heat shock proteins in cancer: Chaperones of tumorigenesis. Trends Biochem. Sci. 2006,31, 164-172.
  • 5Duhem, C.; Ries, F.; Dicato, M. What does multidrug resistance (MDR) expression mean in the clinic. Oncologist 1996,1,151-158.
  • 6Krishna, R.; Mayer, L. D. Multidrug resistance (MDR) in cancer: Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 2000,11,265-283.
  • 7Ferry, D. R.; Traunecker, H.; Kerr, D. J. Clinical trials of P-gJycoprotein reversal in solid tumours. Eur. J. Cancer 1996, 32A, 1070-1081.
  • 8Rowinsky, E. K.; Smith, L.; Wang, Y. M.; Chaturvedi, P.; Villalona, M.; Campbell, E.; Aylesworth, C.; Eckhardt, S. G.; Hammond, L.; Kraynak, M., et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDRI and MRP. J. Clin. Oncol. 1998,16,2964-2976.
  • 9Jabr-Milane, L. S.; van Vlerken, L. E.; Yadav, S.; Amiji, M. M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev. 2008, 34, 592-602.
  • 10Moore, A.; Basilion, J. P.; Chiocca, E. A.; Weissleder, R. Measuring transferrin receptor gene expression by NMR imaging. Biochim. Biophys. Acta-Mol. Cell Res. 1998, 1402, 239-249.

共引文献89

同被引文献20

引证文献5

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部